Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).
Lacuna Pharma Pty Ltd
Head and Neck Squamous Cell Carcinoma (HNSCC)
1 trial -
Etrasimod Arginine Blue
Lacuna Pharma Pty Ltd
Ulcerative Colitis
1 trial -
Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue
Lacuna Pharma Pty Ltd
Crohn's Disease
1 trial -
Eylea 40 mg/mL solution for injection in a vial
Lacuna Pharma Pty Ltd
Retinopathy of prematurity (ROP)
1 trial -
FAT EMULSIONS , Triheptanoin
Lacuna Pharma Pty Ltd
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
1 trial -
Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab
Lacuna Pharma Pty Ltd
Advanced Non-Small Cell Lung Cancer
1 trial -
Fluticasone propionate,Salbutamol sulfate, ProAir® RespiClick®, ProAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate
Lacuna Pharma Pty Ltd
Asthma
1 trial -
Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix
Lacuna Pharma Pty Ltd
Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
1 trial -
Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen
Lacuna Pharma Pty Ltd
Episodic and Chronic Migraine
1 trial -
Furazidin, vaginal tablets, 5mg, Dalacin 20 mg/g hüvelykrém
Lacuna Pharma Pty Ltd
Bacterial vaginosis
1 trial -
GLUCOTHERA PLUS
Lacuna Pharma Pty Ltd
End-stage Kidney Disease
1 trial -
GTX-102, GTX/UX Diluent and Flush Solution
Lacuna Pharma Pty Ltd
Angelman Syndrome
1 trial -
GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)
Lacuna Pharma Pty Ltd
Angelman Syndrome
1 trial -
Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets
Lacuna Pharma Pty Ltd
Chronic Lymphocytic Leukemia
1 trial -
HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.
Lacuna Pharma Pty Ltd
Delayed Sleep-Wake Phase Disorder (DSWPD)
1 trial -
IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules
Lacuna Pharma Pty Ltd
High Risk Chronic Lymphocytic Leukaemia
1 trial -
IMIPENEM, CILASTATIN AND RELEBACTAM, AMIKACIN , TIGECYCLINE , Nacubactam, AZACTAM 1 g, poudre et solution pour usage parentéral, COLISTIN , Cefepime Panpharma, 2 g, proszek do sporządzania roztworu do wstrzykiwań lub infuzji
Lacuna Pharma Pty Ltd
Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)
1 trial -
INZ-701
Lacuna Pharma Pty Ltd
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
1 trial -
INZ-701, INZ-701
Lacuna Pharma Pty Ltd
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
1 trial -
Ibutamoren Mesylate, Ibutamoren Mesylate, Matched placebo capsules administered orally once per day, Ibutamoren Mesylate
Lacuna Pharma Pty Ltd
Growth Hormone Deficiency (GHD)
1 trial -
Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe
Lacuna Pharma Pty Ltd
Psoriatic Arthritis
1 trial -
Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe
Lacuna Pharma Pty Ltd
Psoriatic Arthritis
1 trial -
Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu
Lacuna Pharma Pty Ltd
Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
1 trial -
Impetine® 20mg/g Gel, Bactroban 20 mg/g pomada
Lacuna Pharma Pty Ltd
Impetigo
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources